Ocugen Positive Data and Safety Review Enrollment in Phase 1/2 ArMaDa Study for Geographic Atrophy

 

• Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial
• DSMB Approval to Proceed with Medium Dose Cohort Dosing

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

https://www.biospace.com/article/releases/ocugen-announces-positive-data-and-safety-monitoring-board-review-and-initiation-of-enrollment-in-medium-dose-for-ocu410-a-modifier-gene-therapy-in-phase-1-2-armada-study-for-geographic-atrophy/